# Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients

Study · id `cardio:ct-nct02188186` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02188186](<https://clinicaltrials.gov/study/NCT02188186>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02188186

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT02188186. Randomized; triple masking; primary purpose treatment. Start 2014-07 (actual); primary completion 2018-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT02188186, source copy `cardio:ctgov-nct02188186-2019-03-18`, retrieved 2026-10-26)
- Started: 2014-07 (actual) (ClinicalTrials.gov record NCT02188186, source copy `cardio:ctgov-nct02188186-2019-03-18`, retrieved 2026-10-26)
- Primary completion: 2018-09 (actual) (ClinicalTrials.gov record NCT02188186, source copy `cardio:ctgov-nct02188186-2019-03-18`, retrieved 2026-10-26)
- Completion: 2018-09 (actual) (ClinicalTrials.gov record NCT02188186, source copy `cardio:ctgov-nct02188186-2019-03-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02188186, source copy `cardio:ctgov-nct02188186-2019-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02188186-2019-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients
- Condition: Type 2 Diabetes
- Intervention (Drug): Initial triple combination
- Intervention (Drug): Conventional treatment
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)

## Provenance

Content hash: 8f1a9879953393f075fcad8f6a8f1255f60d2dc4f1c6f4c8d33444bf7fcba83d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
